OQROGet OQRO Pro
Insider trade

Lexicon Pharmaceuticals (LXRX)Director bought ~$76K

Raymond Debbane, Director at Lexicon Pharmaceuticals, bought ~$76K of Lexicon Pharmaceuticals shares.

~$76K
Approx. value · 58K sh @ $1.31
1.44M
Holds after · shares reported
Traded
Feb 13, 2026
Filed
Feb 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 29, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors (and 1 more item)
  2. Jan 29, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 3 more items)
  3. Feb 2, 2026Insider · First insider buy since Nov 2023Director purchased ~$2M of LXRX shares in the open market
  4. Feb 13, 2026 · this disclosureInsider · First buy since 2023Director purchased ~$76K of LXRX shares in the open market

What came next

  1. Feb 17, 2026InsiderDirector purchased ~$101K of LXRX shares in the open market
  2. Feb 18, 2026InsiderDirector purchased ~$176K of LXRX shares in the open market
  3. Feb 19, 2026Insider · 14 days before resultsDirector purchased ~$72K of LXRX shares in the open market
  4. Feb 20, 2026Insider · 13 days before resultsDirector purchased ~$148K of LXRX shares in the open market
  5. Feb 23, 2026Insider · 10 days before resultsDirector purchased ~$147K of LXRX shares in the open market
  6. Feb 25, 2026Insider · 8 days before resultsDirector purchased ~$3K of LXRX shares in the open market
  7. Mar 5, 2026Company filing · Form 8-K · ResultsReported its results
  8. Apr 30, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)
  9. May 4, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  10. May 7, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Lexicon Pharmaceuticals

For Lexicon Pharmaceuticals, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LXRX page.

Other recent filings by Raymond Debbane, Director

The full history of Raymond Debbane, Director is on the profile page.

How this filing works

Other disclosures at Lexicon Pharmaceuticals

Everything OQRO holds on this company is on its LXRX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data